COMPARATIVE-EVALUATION OF THE ANTIHYPERTENSIVE EFFICACY OF ONCE-DAILY AMLODIPINE VERSUS NITRENDIPINE WITH 24-HOUR AMBULATORY BLOOD-PRESSURE MONITORING IN ESSENTIAL-HYPERTENSION

被引:8
作者
COCA, A
PICADO, MJ
DELASIERRA, A
AGUILERA, MT
SANCHEZ, M
LLUCH, MM
URBANOMARQUEZ, A
机构
[1] Hypertension Unit, Department of Internal Medicine, Hospital Clinico, School of Medicine, University of Barcelona
关键词
AMLODIPINE; HYPERTENSION; AMBULATORY BLOOD PRESSURE MONITORING;
D O I
10.1097/00005344-199310000-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We compared the antihypertensive efficacy of once-daily amlodipine (AM) versus nitrendipine (NTR) by 24-h ambulatory blood pressure monitoring (24-h ABPM) in 32 patients with mild to moderate essential hypertension (EH). After a 2-week single-blind, placebo run-in period, patients were randomized in a double-blind, parallel fashion: 14 received AM 5 mg and 18 NTR 10 mg. After 2 weeks, dose was adjusted if necessary (AM 10 mg or NTR 20 mg) and continued for another 6-week period. At the end of the placebo period and during the last week of treatment, patients underwent 24-h ABPM. Initial office BP mean values were similar in both groups (169.8 +/- 14/102.5 +/- 6 vs. 167.1 +/- 14/98.7 +/- 5 mm Hg, respectively, p = NS). A comparable decrease in office mean values of systolic BP (SBP, -22.3 +/- 13 vs. -19.1 +/- 16 mm Hg) and diastolic BP (DBP, -12.0 +/- 5 vs. -8.1 +/- 8 mm Hg) was observed. Nevertheless, 24-h ABPM mean values differed significantly between patients treated with AM or NTR with regard to 24-h SBP (120.0 +/- 10 vs. 132.5 +/- 1 mm Hg, p = 0.01). Moreover, the average decrease in 24-h SBP (-19.3 +/- 6 vs. -5.2 +/- 11 mm Hg, p = 0.0036) and 24-h DBP (-10.7 +/- 4 vs. -3.7 +/- 6 mm Hg, p = 0.0047) was higher in the AM group, with no changes in 24-h heart rate (HR). At equivalent once-daily dosage, AM was more effective than NTR in decreasing BP assessed by 24-h ABPM.
引用
收藏
页码:513 / 518
页数:6
相关论文
共 24 条
  • [1] AMERY A, 1985, LANCET, V1, P1349
  • [2] Beckerman B, 1991, J Cardiovasc Pharmacol, V17 Suppl 1, pS61, DOI 10.1097/00005344-199117001-00019
  • [3] Bernink P J, 1991, J Cardiovasc Pharmacol, V17 Suppl 1, pS53, DOI 10.1097/00005344-199117001-00017
  • [4] CONWAY J, 1991, J HYPERTENS, V9, pS57
  • [5] CONWAY J, 1989, J HYPERTENS, V7, pS29
  • [6] MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION)
    DAHLOF, B
    LINDHOLM, LH
    HANSSON, L
    SCHERSTEN, B
    EKBOM, T
    WESTER, PO
    [J]. LANCET, 1991, 338 (8778) : 1281 - 1285
  • [7] DIRIENZO M, 1985, J HYPERTENS, V3, P343
  • [8] DIXON WJ, 1985, BMDP STATISTICAL SOF
  • [9] Englert R, 1991, J Cardiovasc Pharmacol, V17 Suppl 1, pS22, DOI 10.1097/00005344-199117001-00008
  • [10] THE PHARMACOKINETICS OF AMLODIPINE IN HEALTHY-VOLUNTEERS AFTER SINGLE INTRAVENOUS AND ORAL DOSES AND AFTER 14 REPEATED ORAL DOSES GIVEN ONCE DAILY
    FAULKNER, JK
    MCGIBNEY, D
    CHASSEAUD, LF
    PERRY, JL
    TAYLOR, IW
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) : 21 - 25